US tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocation to the US is impractical. The company will observe evolving situations without taking immediate special actions. Additional costs are anticipated due to the proposed tariff changes. Partnerships and contract manufacturing in the US remain possibilities if beneficial.